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ABSTRACT 
Background and Purpose: 
We report the relation of onset to treatment time (OTT) and door to needle time (DTN) with functional 
outcomes and mortality among ischemic stroke patients with imaging-proven large vessel occlusion 
(LVO) treated with intravenous alteplase.  
Methods: 
Individual patient-level data from the HERMES collaboration were pooled from seven trials that 
randomised patients to mechanical thrombectomy added to best medical therapy versus best medical 
therapy alone. Analysis was restricted to patients who received alteplase directly at the endovascular 
hospital.  The primary outcome was disability defined on the modified Rankin Scale (mRS) at 3 months. 
Results 
Among 601 patients, mean age was 66.0 years (SD 13.9), 50% were women, and median NIHSS score 
was 17. Onset to treatment (OTT) time was median 125 minutes (IQR 90-170). Door-to-treatment time 
was median 38 minutes (IQR 26-55).  Each 60-minute OTT delay was associated with greater disability at 
90 days; the odds of functional independence (mRS 0-2) at 90 days was OR 0.82 (95%CI, 0.66 to 1.03).  
With each 60-minute delay in door-to-needle time, the odds of functional independence was OR 0.55 
(95%CI, 0.37 to 0.81) at 90 days.  The absolute decline in the rate of excellent outcome (mRS 0-1 at 90 
days) was 20.3 per 1000 patients treated per 15 minutes delay in door-to-needle time.  The adjusted 
absolute risk difference for a door-to-needle time < 30 min vs. 30-60 min was 19.3% for independent 
outcome (NNT ~ 5 to gain one additional good outcome). SICH occurred in 3.4% of patients, without a 
significant time dependency: OR 0.74 (95CI 0.43-1.28). 
Conclusion 
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Faster intravenous thrombolysis delivery is associated with less disability at 3 months among patients 
with large vessel occlusion.   
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INTRODUCTION 
Multiple randomised controlled trials (RCTs) have demonstrated the superiority of endovascular 
thrombectomy(EVT) in combination with intravenous alteplase over alteplase alone among patients with 
ischemic stroke due to large vessel occlusion (LVO).1 Prior evidence shows a time-dependent benefit of 
alteplase among all fibrinolysis-eligible patients with acute ischaemic stroke within 4.5 hours.2  However,  
alteplase alone yields lower early reperfusion rates in patients with large vessel occlusions, compared 
with medium and small vessel occlusions, and the degree and time-dependence of benefit of alteplase in 
LVO stroke patients is less well understood since RCTs comparing intravenous alteplase to control did 
not require pre-treatment neurovascular imaging.3, 4  Better understanding of these aspects of alteplase 
treatment would be helpful in determining the risks and benefits of delaying alteplase start but hastening 
thrombectomy start by ambulance routing of patients directly to interventional stroke centers. 
Additionally, the number of exclusion criteria for alteplase therapy, its cost, the time required for its 
mixing and infusion and safety considerations are cited reasons5 to justify trials randomizing LVO 
patients destined to undergo EVT to either receive alteplase therapy vs. placebo. 6 
Prior data on alteplase use in proven LVO cohorts are limited. Some studies relied on transcranial 
Doppler to diagnose the presence of intracranial occlusions, which is an operator-dependent technique 
and which also might confound observational studies by introducing a sonothrombolysis treatment 
effect.7 With the recent advent of large-scale endovascular thrombectomy trials and routine endovascular 
thrombectomy practice, there has been a shift in the standard stroke imaging paradigm with acute 
intracranial vessel imaging becoming a routine modality.  In a meta-analysis, intravenous alteplase 
showed greater effect among patients with proven pre-treatment occlusion.8   Recent successful 
randomised controlled trials of EVT relied on CT or MR angiography to detect the occlusion location. 
Some of the trials used at least one extra imaging modality to assess collaterals or brain perfusion to select 
patients most likely to benefit from revascularization therapies.9-15 We pooled individual patient data from 
patients with LVO treated with intravenous alteplase alone in the controls arms of seven recent RCTs of 
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EVT, and explored the impact of interval times adjusting for important prognostic clinical and imaging 
variables on functional recovery and adverse outcome. 
 
METHODS 
The Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration was formed by the trial investigators of ESCAPE, EXTEND-IA, MR CLEAN, PISTE, 
REVASCAT, SWIFT PRIME and THRACE. We searched Pubmed for randomized trials published 
between 1 Jan 2010 and 31 May 2017 comparing endovascular thrombectomy performed using 
predominantly stent-retrievers with standard care in anterior circulation ischaemic stroke patients - 
Pubmed search string: (("randomized controlled trial"[Publication Type]) AND 
((thrombectomy[Title/Abstract]) OR (clot retrieval[Title/Abstract]) OR intraarterial[Title/Abstract]) AND 
(stroke[Title/Abstract]) AND ("2010/01/01"[Date - Publication] : "2017/05/31"[Date - Publication])).  
The design and selection criteria of these trials and the HERMES collaboration have been previously 
described.1 In brief, these trials randomised patients to receive EVT using retrievable stents (in most 
patients) plus medical therapy vs. medical therapy alone in anterior circulation ischaemic stroke patients.  
The current study included only medical therapy (control) arm patients who received intravenous 
alteplase.    From this population, we excluded patients who received alteplase in a peripheral hospital 
prior to transfer to the endovascular center, since among these patients the RCTs selectively enrolled only 
alteplase-failure patients, Alteplase was administered according to clinical routine standard care with a 
total dose of 0.9 mg/kg with 10% of the dose given as a bolus and the remainder infused over an hour.   
All participants provided informed consent according to each trial protocol and each study was approved 
by the local ethics board. 
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This meta-analysis was prospectively designed by the HERMES executive committee but not registered. 
Data were contributed by the authors of all the trials meeting eligibility criteria and collated by 
independent statisticians. All data relevant to the analyses presented were part of each study’s individual 
design and data collection and are part of the general HERMES database.  No standardization or 
translation of the fields employed for analysis and reporting was necessary. After collation of data, key 
fields were compared to original results, including published data.  No major discrepancies were found 
and minor discrepancies were resolved in collaboration with the study authors/investigators. The principal 
risk of bias derived from differences among individual studies’ methods and inclusion criteria. 
Outcomes 
Global disability status at 90 days was assessed using the modified Rankin Scale (mRS).  The primary 
outcome was the degree of disability at 90 days on the mRS, tested with the common odds ratio from a 
proportional odds model. Categories 5 and 6 were collapsed into one resulting in a 6-level scale.  
Secondary efficacy outcomes were: excellent recovery (mRS 0-1) and independent recovery (mRS 0-2). 
Safety outcomes were death (mRS 6) and symptomatic intracranial haemorrhage (sICH) defined within 
each trial.  
Statistical Analysis 
We assessed outcomes using generalised linear mixed models, including a cumulative logit link function 
for the multinomial primary outcome of mRS and a logit link function for all other (binomial) outcomes.  
In all models, a term for study was included as a random effect to account for study-level variation.  The 
relation between time and outcomes was adjusted for age, sex, baseline NIHSS score, ASPECT score and 
occlusion location. We also assessed for evidence of interaction between time and key baseline factors 
(age, sex, baseline NIHSS score, ASPECT score, occlusion location, diabetes mellitus, atrial fibrillation, 
and prior stroke).  We calculated the rate of decline in benefit per 1000 patients treated by assuming 
linearity of the relationship and then calculating the slope of the line. All statistical analyses were 
performed in SAS version 9·4 (SAS Institute, Cary, NC, USA) and R version 3·2 (R Foundation for 
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Statistical Computing, Vienna, Austria). P-values were two-sided and p<0·05 indicated statistical 
significance in all analyses. 
Role of the funding source 
The funder of the study had no role in study design, data collection, analysis, or interpretation, writing of 
this article, or the decision to submit this study for publication. The corresponding author had full access 
to all the data in the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
Among 893 patients in the control arms, 86 (9.6%) were excluded as being alteplase-ineligible and 206 
(23.1%) as receiving alteplase at a non-endovascular center, leaving 601 (67.3%) receiving alteplase at 
the endovascular hospital. Among these 601 patients, mean age was 66.0 years (SD 13.9), 50% were 
women, and median NIHSS score was 17 (IQR 13-21). The median time from onset to intravenous 
alteplase start was 165 minutes (IQR 130-203), with 82% treated within 3 hours from onset and 17% 
between 3-4.5 hours. The median door-to-alteplase-treatment time was 38 minutes (IQR 26 – 55).  Patient 
characteristics according to onset to treatment time in early (0-90 minutes), intermediate (91-180 
minutes), and late (181-270 minutes) windows are shown in Table 1. Patients in each time treatment 
epoch were well-matched with respect to age and sex.  Earlier-treated patients were less likely to have a 
history of hypertension and hyperlipidaemia, less severe infarct signs on imaging (higher ASPECT 
scores), higher acute serum glucose levels, more often had occlusions in the internal carotid artery (ICA) 
and presented with more severe deficits (higher NIHSS scores). 
At 90 days, 20.2% (118/583) achieved excellent recovery (mRS 0-1) and 34.1% (199/583) achieved 
independent functional recovery (mRS 0-2). In adjusted analyses, the odds of better disability outcomes at 
90 days (mRS scale distribution) in the alteplase group declined with longer time from symptom onset to 
treatment (Table 2). Each 60-minute delay in therapy was associated with a less favourable degree of 
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disability, cOR 0.80 (95% CI 0.68 to 0.95). Each 60-minute delay was also associated with reduced odds 
of excellent recovery (mRS 0-1), OR 0.76 (95% CI, 0.58 to 0.99), and a trend toward reduced odds of 
functional independence (mRS 0-2), OR 0.82 (95% CI, 0.66 to 1.03).  In adjusted analysis, the absolute 
risk difference (ARD) for functional independence between the onset-to-treatment of 0.5-3 hours vs. 3-4.5 
hours was 4.5% (32.3% vs 27.8%, Figure 1).  Among 42 patients with very fast onset-to-treatment times 
of 30-60 minutes, the adjusted rate of functional independence at 90 days was 37.5%. 
The decline in the rate of good outcomes with longer onset-to-treatment was not modified by age 
(heterogeneity p=0.21), baseline NIHSS score (heterogeneity p=0.81), baseline ASPECT score 
(heterogeneity p=0.88), occlusion location (heterogeneity p=0.67), diabetes mellitus (heterogeneity 
p=0.44), prior stroke (heterogeneity p=0.27), or sex (heterogeneity p=0.21) (Figure 2). The absolute 
decline in the rate of excellent outcome (mRS 0-1 at 90 days) was 8.4 per 1000 patients treated per 15 
minutes delay in onset-to-treatment time. 
The relation between door to needle time and outcome was stronger than onset to needle time. The odds 
of excellent recovery (mRS 0-1) and functional independence (mRS 0-2) for each 60-minute delay in 
door-to-needle was OR (mRS 0-1) 0.51 (95%CI, 0.29 to 0.92) and OR (mRS 0-2) 0.47 (95%CI, 0.28 to 
0.80) respectively.  The adjusted absolute risk difference for lower functional independence between 
door-to-needle time intervals of 0-30 vs. 31-60 minutes was 19.3% (45.0% vs 25.7%).  The absolute 
decline in the rate of excellent outcome (mRS 0-1 at 90 days) was 20.3 per 1000 patients treated per 15 
minutes delay in door-to-needle time.  There was no evidence of an onset-to-treatment time effect on 
mortality or symptomatic intracranial haemorrhage (Table 2).   
 
DISCUSSION 
In this pooled analysis of individual participant-level data of acute ischaemic stroke patients with 
documented large vessel occlusion receiving alteplase alone, 20% of patients achieved excellent 
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functional outcome at 90 days. Slower initiation of alteplase therapy was associated with worse outcomes 
over the entire disability range and lower rates of excellent recovery and functional independence.  In 
contrast, death and symptomatic intracranial haemorrhage did not show onset to treatment time 
dependency.  The rate of decline of benefit with time from symptom onset was modest, though clinically 
relevant at the systems level; among LVO patients, every 15-minute delay in alteplase start is associated 
with 8 fewer among 1000 patients achieving excellent (mRS 0-1) outcome at 90 days.  In contrast, the 
rate of decline of benefit with time from hospital arrival (door-to-needle time) was more dramatic among 
LVO patients, every 15-minute delay in alteplase start is associated with 20 fewer among 1000 patients 
achieving excellent (mRS 0-1) outcome at 90 days.   
 
These findings are consonant with prior studies demonstrating that alteplase treatment is of benefit for a 
broad range of patients with acute ischaemic stroke treated within 3 hours,16 and within 3 to 4.5 hours 
from the last seen well time.17 Treatment outcomes in general clinical practice accord with those in the 
pivotal RCTs, in diverse geographic regions and healthcare systems.18-20 Among this broad patient group, 
both pooled clinical trials and large clinical practice registries also demonstrated a large time-dependency 
of benefit from treatment with intravenous alteplase, with treatment sooner after onset associated with 
improved outcomes.2, 21, 22   Disability outcomes at 3 months after treatment with intravenous alteplase 
alone were less favourable among the LVO patients in the current investigation than among broader 
cohorts previously investigated.  The overall rate of functional independence at 90 days among LVO 
patients of 34% in the current study is much less than the 44% seen among a broader cohort in the pooled 
pivotal intravenous alteplase trials.23  This less favourable outcome rate is consistent with the greater 
presenting deficit severity and the reduced early reperfusion response of LVO compared to non-LVO 
patients. 
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The pace of loss of benefit from stroke onset to alteplase therapy specifically in LVO patients, observed 
in the current study, appears slightly faster than that for the broader group of all alteplase-eligible patients. 
Direct comparison with prior studies is not possible because the time-benefit curve analysis of pooled 
patients from all alteplase trials reported changes with onset-to-treatment in the odds ratio for better 
outcomes with alteplase versus control, but not the speed of decline in good outcomes within the 
alteplase-treated group.2  The time-benefit curve analysis of patients treated in practice in the US national 
Get with the Guidelines – Stroke registry reported changes with onset-to-treatment in rates of good 
outcome at discharge, rather than at 90 days but the results are similar.21  In the current study, a fifteen-
minute delay in start of alteplase was associated with 8 fewer of 1000 LVO patients achieving excellent 
(mRS 0-1) outcome at 90 days; in the US national registry study, a fifteen-minute delay in start of 
alteplase was associated with 7 fewer of 1000 mixed LVO and non-LVO patients achieving excellent 
(mRS 0-1) outcome at hospital discharge. 
 
A critical observation from the current study is the documentation of the very large absolute magnitude of 
benefit with fast door-to-needle times, with an estimated number-needed-treat of 5 to achieve one 
additional independent outcome with treatment less than 30 minutes from hospital arrival compared to 
greater than 30 minutes.  This result implies an imperative to set standards for in hospital processes much 
more aggressively than currently.  While ultimately the onset-to-reperfusion times will physiologically 
govern the chance of good outcome, the patients in the HERMES analysis were largely selected by 
imaging characteristics such that patients with very large infarcts (on non-contrast CT, MR or predicted 
by CTP) or poor pial collateral filling were excluded.  This meant that the onset-to-imaging time was less 
important than the imaging-to-treatment times in predicting outcomes.  In addition, there is substantive 
inaccuracy of documented last known well times, dependent on the recall of patients with acute brain 
insults or on symptom recognition by proxy observer, introducing noise into onset-to-treatment intervals 
absent from door-to-needle intervals.  These physiological, measurement and trial design factors likely 
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contribute to the large magnitude of effect size difference between door-to-needle time and onset-to-
treatment times. 
 
The decline in benefit due to delays from onset-to-treatment with alteplase therapy alone in LVO patients 
in the current study is 2.5-fold less (8 vs 20 fewer per thousand independent outcomes per 15 minute 
delay) than that for endovascular thrombectomy in LVO patients in a prior US national Get with the 
Guidelines – Stroke study.24  This is consistent with the larger overall treatment benefit magnitude 
associated with endovascular therapy.  However, patient selection by imaging may also play a role in the 
shallow onset-to-treatment time decay curves for intravenous alteplase treatment patients, by excluding 
patients with fast progression of ischemia.  Although the Get-with-the-Guidelines data are voluntarily 
collected and reported compared to the more rigorous prospective clinical trial data presented here, these 
contrasting time-benefit relationships are important inputs into models seeking to optimise ambulance 
routing strategies for patients with suspected LVO, since direct routing to comprehensive stroke centres 
will cause longer onset to treatment for alteplase but shorter onset to puncture for thrombectomy.25, 26 
 
Biologically, our results may be partly explained because the probability of early reperfusion with 
intravenous alteplase only is less than half that with EVT.  In the ESCAPE trial,10 recanalization was 
measured in the control arm at 2-8 hours after randomization using CT angiography.  Despite differences 
in sub-populations, the rate of early recanalization was 7% in those who were not eligible for and did not 
receive alteplase, 37% in those who received alteplase alone and 75% in those who received EVT 
(determined by formal selective cerebral angiography).10  Key baseline patient factors, including stroke 
severity and the extent of early ischemic changes, did not alter the time relationship with treatment.  
Although the European regulation labelling for alteplase in the 3-to-4.5-hour time window, using ECASS-
3 data,17 initially suggested that patients over age 80, with diabetes mellitus or very severe stroke should 
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not be offered treatment with alteplase, our analyses provide collateral prospective observational evidence 
that fast treatment is the more important issue.   
 
This study has limitations. Entry criteria differed in some ways across the 7 contributing trials, most 
notably with 3 of the trials requiring or encouraging the use of more advanced imaging of penumbra or 
collaterals. However, among patients with LVO, almost all patients have adequate penumbra or 
collaterals within the first 4.5 hours from onset. Only one trial collected data on early reperfusion 
subsequent to alteplase use, precluding detailed analysis. We made a simplifying assumption that all 
patients treated at the endovascular hospital had CTA prior to or immediately after commencing alteplase 
therapy; however, it remains possible that this was not the case in a small number of patients.  The nature 
of some of the trial protocols resulted in an enriched cohort who did not reperfuse with intravenous 
alteplase (“non-responders”) which may have resulted in an underestimate of the rate of excellent 
neurological outcome.  Finally, even after pooling across trials, sample size was moderate, limiting 
precision of time-benefit relation estimates. 
 
In conclusion, disability outcomes at 3 months with alteplase alone are less favourable with slower onset 
to treatment times.  Faster treatment, in particular door-to-needle times less than 30 minutes, are strongly 
associated with better outcomes. 
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Table 1 1 
Baseline characteristics of the alteplase cohort according to onset to treatment times.  2 
Metric 
All 
(n 601) 
OTT 0-90 min 
(n 158) 
OTT 91-180 min 
(n 336) 
OTT 181-270 min 
(n 99) p-value 
Age (years) 66.0 ± 13.9 (601)  
[68.0] (18.0,96.7) 
66.7 ± 12.8 (158)  
[68.0] (34.0,96.7) 
65.4 ± 13.8 (336)  
[68.0] (18.0,90.0) 
66.3 ± 15.5 (99)  
[69.0] (20.4,90.0) 
0.673 
Age 80+ 12.0% (72/601) 12.7% (20/158) 10.4% (35/336) 13.1% (13/99) 0.652 
Female sex  50.1% (301/601) 46.2% (73/158) 52.7% (177/336) 46.5% (46/99) 0.306 
Medical History 
     
Atrial fibrillation 31.0% (112/361) 27.0% (38/141) 32.3% (52/161) 37.7% (20/53) 0.312 
Hypertension 59.6% (357/599) 54.1% (85/157) 57.4% (193/336) 75.8% (75/99) 0.001 
Hyperlipidemia 42.1% (245/582) 30.8% (48/156) 46.6% (152/326) 45.2% (42/93) 0.003 
Diabetes mellitus 18.1% (108/598) 16.6% (26/157) 18.2% (61/336) 19.4% (19/98) 0.838 
Prior stroke/TIA 9.4% (56/598) 7.0% (11/158) 9.3% (31/334) 14.1% (14/99) 0.158 
Tobacco use 37.0% (204/551) 35.6% (52/146) 39.4% (123/312) 32.2% (28/87) 0.416 
Glucose (mg/ dl) 
(mean, sd (n),  median, range) 
86.3 ± 87.0 (561)  
[102.6] (0.0,1236.4) 
124.1 ± 101.4 (151)  
[115.0] (0.8,1236.4) 
70.6 ± 78.5 (310)  
[87.6] (0.0,457.0) 
74.3 ± 70.4 (93)  
[101.8] (0.4,315.0) 
<0.001 
Pre-stroke mRS 
    
0.810 
0 82.2% (296/360) 80.9% (114/141) 82.6% (133/161) 86.5% (45/52) 
 
1 11.9% (43/360) 12.1% (17/141) 11.8% (19/161) 11.5% (6/52) 
 
2  2.8% (10/360)  3.5% (5/141)  1.9% (3/161)  1.9% (1/52) 
 
3+  3.1% (11/360)  3.5% (5/141)  3.7% (6/161)  0.0% (0/52) 
 
NIHSS at baseline 16.8 ± 5.2 (599)  
[17.0] (4.0,32.0) 
17.1 ± 5.7 (158)  
[17.0] (4.0,32.0) 
17.0 ± 4.9 (335)  
[17.0] (4.0,29.0) 
15.9 ± 5.1 (99)  
[16.0] (4.0,25.0) 
0.098 
NIHSS at baseline 
    
0.101 
  0-10 13.0% (78/599) 17.1% (27/158)  9.6% (32/335) 17.2% (17/99) 
 
  11-15 25.9% (155/599) 19.6% (31/158) 28.7% (96/335) 27.3% (27/99) 
 
  16-20 35.6% (213/599) 36.7% (58/158) 36.4% (122/335) 32.3% (32/99) 
 
  21+ 25.5% (153/599) 26.6% (42/158) 25.4% (85/335) 23.2% (23/99) 
 
Occlusion location 
    
0.063 
  NA  6.8% (41/601)  4.4% (7/158)  7.4% (25/336)  8.1% (8/99) 
 
  ICA 24.0% (144/601) 32.9% (52/158) 19.9% (67/336) 23.2% (23/99) 
 
  M1-MCA 63.2% (380/601) 56.3% (89/158) 65.5% (220/336) 66.7% (66/99) 
 
  M2-MCA  5.8% (35/601)  6.3% (10/158)  6.8% (23/336)  2.0% (2/99) 
 
  Other  0.2% (1/601)  0.0% (0/158)  0.3% (1/336)  0.0% (0/99) 
 
ASPECTS 7.6 ± 2.1 (594)  
[8.0] (0.0,10.0) 
8.0 ± 1.8 (155)  
[8.0] (1.0,10.0) 
7.2 ± 2.2 (334)  
[8.0] (0.0,10.0) 
7.8 ± 1.9 (98)  
[8.0] (2.0,10.0) 
0.168 
ASPECTS 
    
<0.001 
  9-10 33.8% (201/594) 44.5% (69/155) 25.7% (86/334) 43.9% (43/98) 
 
  7-8 45.1% (268/594) 40.6% (63/155) 50.9% (170/334) 33.7% (33/98) 
 
  5-6 12.5% (74/594)  8.4% (13/155) 13.2% (44/334) 15.3% (15/98) 
 
  0-4  8.6% (51/594)  6.5% (10/155) 10.2% (34/334)  7.1% (7/98) 
 
Onset to ED (min) 92.4 ± 58.3 (562)  
[80.0] (0.0,466.0) 
40.3 ± 17.0 (148)  
[40.0] (0.0,86.0) 
88.1 ± 31.7 (314)  
[86.0] (0.0,180.0) 
172.3 ± 35.5 (93)  
[180.0] (63.0,246.0) 
<0.001 
Onset to alteplase treatment 
(min) 
133.7 ± 60.4 (600)  
[125.0] (31.0,525.0) 
69.7 ± 14.8 (158)  
[70.0] (31.0,90.0) 
133.5 ± 26.2 (336)  
[133.0] (91.0,180.0) 
218.9 ± 25.5 (99)  
[219.0] (183.0,270.0) 
<0.001 
ED arrival to alteplase treatment 
(min) 
42.0 ± 24.4 (562)  
[38.0] (0.0,157.0) 
29.3 ± 14.8 (148)  
[29.0] (0.0,89.0) 
46.0 ± 24.1 (314)  
[43.0] (0.0,125.0) 
47.7 ± 30.4 (93)  
[42.0] (0.0,157.0) 
<0.001 
OTT = onset-to-alteplase-treatment time (minutes): TIA = transient ischemic attack; mRS = modified Rankin scale; NIHSS = National 3 
Institutes of Health Stroke Scale; ICA = internal carotid artery; M1-MCA = M1 segment (stem) of the middle cerebral artery; M2-MCA 4 
= M2 segment (branch) of the middle cerebral artery; ASPECTS = Alberta Stroke Program Early CT Score; ED = emergency 5 
department; 6 
 7 
  8 
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Table 2 
Effect of onset-to-treatment and door-to-needles times on adjusted patient outcomes. 
Outcome * Onset-to-Treatment time (per 60 min) 
Odds ratio (95% confidence interval) 
Door-to-Needle time (per 60 min) 
Odds ratio (95% confidence interval) 
mRS (ordinal) 0.80 (CI95 0.68-0.95) 0.55 (CI95 0.37-0.81) 
mRS 0-2 0.82 (CI95 0.66-1.03) 0.47 (CI95 0.28-0.80) 
mRS 0-1 0.76 (CI95 0.58-0.99) 0.51 (CI95 0.29-0.92) 
Death 0.99 (CI95 0.79-1.23) 1.07 (CI95 0.59-1.93) 
sICH 0.74 (CI95 0.43-1.28) 0.44 (CI95 0.12-1.66) 
mRS = modified Rankin Scale, sICH = symptomatic intracerebral haemorrhage; CI95 = 95% confidence interval 
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Figure 1 
Relationship between onset to treatment time (Figure 1a) and door to treatment time (Figure 1b) with 
alteplase and the proportion of patients with 90-day functional independence (mRS 0-2 “in black”) and 
90-day excellent functional recovery (mRS 0-1 “in red”).  Curves are adjusted for age, sex, NIHSS, 
ASPECTS, occlusion location.  Curves have a different breadth along the time axis (abscissa) which 
attenuates the relative steepness of the slope of ED-arrival-to-tPA-delivery curve.  A fifteen-minute delay 
in start of alteplase from stroke onset was associated with 8 fewer of 1000 LVO patients achieving 
excellent (mRS 0-1) outcome at 90 days; but the loss of benefit is steeper with a fifteen-minute delay in 
start of alteplase from ED arrival associated with 20 fewer of 1000 LVO patients achieving excellent 
(mRS 0-1) outcome at 90 days. 
 
A       B 
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Figure 2: 
Relation between time from onset to alteplase treatment and functional independence (mRS 0-2) at 3 
months in patient subgroups of site of vessel occlusion (A), extent of infarct signs (ASPECT score) (B), 
age, (C), and presenting stroke deficit severity (NIHSS) (D).  
ASPECTS: Alberta Stroke Program Early CT Score, ICA: terminal internal carotid artery, M1: proximal 
middle cerebral artery “M1”; mRS=modified Rankin Scale. NIHSS=National Institutes of Health Stroke 
Scale 
A 
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